Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CAESAR KYLE LUO

Allopathic & Osteopathic Physicians Ophthalmology Retina Specialist

NPI
1669684072
CMS profile
348753
Location
WALNUT CREEK, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$60,993.79

90 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 2; records 51–90 of 90 matching records. This page contains 40 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CAESAR KYLE LUO

NPI 1669684072 · CMS profile ID 348753

Allopathic & Osteopathic Physicians / Ophthalmology / Retina Specialist

WALNUT CREEK, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–90 of 90 matching records. This page contains 40 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1669684072?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CAESAR KYLE LUO, NPI 1669684072, CMS profile ID 348753. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–90 of 90 matching records. This page contains 40 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1669684072?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). CAESAR KYLE LUO, NPI 1669684072, CMS profile ID 348753. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–90 of 90 matching records. This page contains 40 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1669684072?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
CAESAR KYLE LUO, NPI 1669684072, CMS profile ID 348753, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–90 of 90 matching records. This page contains 40 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1669684072?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

90 matching records · $60,993.79 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 90 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–90 of 90.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Regeneron Healthcare Solutions, Inc. $4,230.0006/04/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1212978845 CMS
Regeneron Healthcare Solutions, Inc. $584.2106/02/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1212978839 CMS
Regeneron Healthcare Solutions, Inc. $105.4005/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212978833 CMS
Regeneron Healthcare Solutions, Inc. $33.1705/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212978835 CMS
Regeneron Healthcare Solutions, Inc. $36.4605/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212978837 CMS
ANI Pharmaceuticals, Inc. $31.5205/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248602587 CMS
Genentech USA, Inc. $34.9905/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211500405 CMS
Regeneron Healthcare Solutions, Inc. $798.9705/20/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1212978831 CMS
Regeneron Healthcare Solutions, Inc. $17.2805/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212978829 CMS
ANI Pharmaceuticals, Inc. $26.0905/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248609036 CMS
ABBVIE INC. $9.5305/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202334638 CMS
Genentech USA, Inc. $32.0804/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211500407 CMS
Regeneron Healthcare Solutions, Inc. $9,400.0004/25/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1212978827 CMS
ABBVIE INC. $7.2904/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202334636 CMS
ANI Pharmaceuticals, Inc. $29.7604/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248615907 CMS
Regeneron Healthcare Solutions, Inc. $131.8304/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212978825 CMS
Regeneron Healthcare Solutions, Inc. $378.1504/16/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1212978823 CMS
Regeneron Pharmaceuticals, Inc. $18.8304/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213240603 CMS
Regeneron Healthcare Solutions, Inc. $570.7004/11/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1212978821 CMS
Regeneron Healthcare Solutions, Inc. $35.0804/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212978819 CMS
ABBVIE INC. $9.9204/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202334634 CMS
Genentech USA, Inc. $2,995.0004/05/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1211500403 CMS
ABBVIE INC. $119.0703/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202334632 CMS
Ocular Therapeutix, Inc. $45.7703/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250226710 CMS
Astellas Pharma US Inc $37.5003/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238759140 CMS
Apellis Pharmaceuticals, Inc. $29.7503/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1253190942 CMS
Astellas Pharma US Inc $30.5303/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238768456 CMS
Carl Zeiss Meditec USA, Inc. $31.4803/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249352135 CMS
Genentech USA, Inc. $26.3502/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211500395 CMS
Mallinckrodt Hospital Products Inc. $13.8602/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211980090 CMS
Ocular Therapeutix, Inc. $110.8302/12/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1250226714 CMS
Astellas Pharma US Inc $32.5602/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238744458 CMS
Genentech USA, Inc. $21.9201/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211500401 CMS
ABBVIE INC. $6.1801/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202334630 CMS
Regeneron Pharmaceuticals, Inc. $21.5601/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213240601 CMS
Ocular Therapeutix, Inc. $1,082.9001/17/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1250226716 CMS
Ocular Therapeutix, Inc. $67.7501/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250226712 CMS
Ocular Therapeutix, Inc. $40.8701/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250226718 CMS
Ocular Therapeutix, Inc. $319.2501/15/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1250226720 CMS
Ocular Therapeutix, Inc. $759.4601/15/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1250226722 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $104,460.19 178
PY2020 $16,641.53 42
PY2021 $25,104.92 26
PY2022 $23,357.09 58
PY2023 $41,803.29 53
PY2024 $21,755.02 52
PY2025 $60,993.79 90

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $10,273.86 1
PY2025 Principal investigator $729,866.80 263
PY2024 Principal investigator $96,439.21 22
PY2023 Principal investigator $132,988.58 5
PY2022 Principal investigator $71,097.80 3
PY2021 Principal investigator $23,264.30 11
PY2019 Principal investigator $20,814.00 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

264 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ocular Therapeutix, Inc. $200.00 12/31/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230688
Principal investigator 1 Ocular Therapeutix, Inc. $550.00 12/31/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230691
Principal investigator 1 Ocular Therapeutix, Inc. $550.00 12/31/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230695
Principal investigator 1 Ocular Therapeutix, Inc. $550.00 12/31/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230699
Principal investigator 1 Ocular Therapeutix, Inc. $300.00 12/31/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230703
Principal investigator 1 Boehringer Ingelheim International GmbH $4,576.60 12/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778514
Principal investigator 1 Ocular Therapeutix, Inc. $300.00 12/19/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230683
Principal investigator 1 Ocular Therapeutix, Inc. $20,664.00 12/17/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230679
Principal investigator 1 Ocular Therapeutix, Inc. $2,700.00 12/15/2025 Non-covered Recipient Entity
Bay Area Retina Associates (Walnut Creak) - 20-070
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230715
Principal investigator 1 Ocular Therapeutix, Inc. $1,084.40 12/12/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230676
Principal investigator 1 Boehringer Ingelheim International GmbH $1,296.00 12/10/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778492
Principal investigator 1 Boehringer Ingelheim International GmbH $34.67 12/10/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778504
Principal investigator 1 Boehringer Ingelheim International GmbH $34.67 12/10/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778506
Principal investigator 1 Boehringer Ingelheim International GmbH $34.67 12/10/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778508
Principal investigator 1 Boehringer Ingelheim International GmbH $34.67 12/10/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778518
Principal investigator 1 Boehringer Ingelheim International GmbH $34.67 12/10/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778520
Principal investigator 1 Boehringer Ingelheim International GmbH $30.82 12/10/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778522
Principal investigator 1 Boehringer Ingelheim International GmbH $34.67 12/10/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778528
Principal investigator 1 Ocular Therapeutix, Inc. $439.60 12/10/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230668
Principal investigator 1 Ocular Therapeutix, Inc. $200.00 12/10/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230672
Principal investigator 1 Boehringer Ingelheim International GmbH $19.64 12/08/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778488
Principal investigator 1 Boehringer Ingelheim International GmbH $11.73 12/08/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778494
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 12/08/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778498
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 12/08/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778510
Principal investigator 1 Boehringer Ingelheim International GmbH $750.00 12/04/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778526
Principal investigator 1 Boehringer Ingelheim International GmbH $218.00 12/03/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778490
Principal investigator 1 Boehringer Ingelheim International GmbH $262.00 12/03/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778496
Principal investigator 1 Boehringer Ingelheim International GmbH $166.00 12/03/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778500
Principal investigator 1 Boehringer Ingelheim International GmbH $246.00 12/03/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778502
Principal investigator 1 Boehringer Ingelheim International GmbH $186.00 12/03/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778512
Principal investigator 1 Boehringer Ingelheim International GmbH $186.00 12/03/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778516
Principal investigator 1 Boehringer Ingelheim International GmbH $180.00 12/03/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778524
Principal investigator 1 Boehringer Ingelheim International GmbH $166.00 12/03/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778530
Principal investigator 1 Ocular Therapeutix, Inc. $17,444.40 12/01/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230660
Principal investigator 1 Ocular Therapeutix, Inc. $17,444.40 12/01/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230664
Principal investigator 1 Boehringer Ingelheim International GmbH $4,158.00 11/27/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778410
Principal investigator 1 Boehringer Ingelheim International GmbH $750.00 11/26/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778450
Principal investigator 1 Boehringer Ingelheim International GmbH $308.00 11/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778404
Principal investigator 1 Boehringer Ingelheim International GmbH $204.40 11/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778406
Principal investigator 1 Boehringer Ingelheim International GmbH $106.40 11/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778408
Principal investigator 1 Boehringer Ingelheim International GmbH $236.60 11/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778416
Principal investigator 1 Boehringer Ingelheim International GmbH $72.80 11/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778418
Principal investigator 1 Boehringer Ingelheim International GmbH $236.60 11/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778420
Principal investigator 1 Boehringer Ingelheim International GmbH $72.80 11/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778422
Principal investigator 1 Boehringer Ingelheim International GmbH $173.60 11/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778424
Principal investigator 1 Boehringer Ingelheim International GmbH $64.40 11/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778428
Principal investigator 1 Boehringer Ingelheim International GmbH $236.60 11/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778432
Principal investigator 1 Boehringer Ingelheim International GmbH $252.00 11/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778436
Principal investigator 1 Boehringer Ingelheim International GmbH $236.60 11/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778438
Principal investigator 1 Boehringer Ingelheim International GmbH $64.40 11/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778440
Principal investigator 1 Boehringer Ingelheim International GmbH $236.60 11/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778442
Principal investigator 1 Boehringer Ingelheim International GmbH $236.60 11/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778444
Principal investigator 1 Boehringer Ingelheim International GmbH $236.60 11/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778448
Principal investigator 1 Boehringer Ingelheim International GmbH $236.60 11/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778452
Principal investigator 1 Boehringer Ingelheim International GmbH $506.80 11/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778454
Principal investigator 1 Boehringer Ingelheim International GmbH $236.60 11/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778456
Principal investigator 1 Boehringer Ingelheim International GmbH $173.60 11/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778458
Principal investigator 1 Boehringer Ingelheim International GmbH $64.40 11/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778462
Principal investigator 1 Boehringer Ingelheim International GmbH $64.40 11/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778464
Principal investigator 1 Boehringer Ingelheim International GmbH $64.40 11/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778472
Principal investigator 1 Boehringer Ingelheim International GmbH $296.80 11/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778474
Principal investigator 1 Boehringer Ingelheim International GmbH $560.00 11/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778476
Principal investigator 1 Boehringer Ingelheim International GmbH $296.80 11/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778478
Principal investigator 1 Boehringer Ingelheim International GmbH $506.80 11/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778480
Principal investigator 1 Boehringer Ingelheim International GmbH $64.40 11/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778482
Principal investigator 1 Boehringer Ingelheim International GmbH $560.00 11/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778484
Principal investigator 1 Boehringer Ingelheim International GmbH $191.80 11/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778486
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 11/19/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778542
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 11/19/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778544
Principal investigator 1 Boehringer Ingelheim International GmbH $80.04 11/19/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778546
Principal investigator 1 Ocular Therapeutix, Inc. $1,168.40 11/19/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230656
Principal investigator 1 Boehringer Ingelheim International GmbH $4,158.00 11/12/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778426
Principal investigator 1 Boehringer Ingelheim International GmbH $1,817.20 11/12/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778430
Principal investigator 1 Boehringer Ingelheim International GmbH $4,158.00 11/12/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778468
Principal investigator 1 Ocular Therapeutix, Inc. $550.00 11/12/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230644
Principal investigator 1 Ocular Therapeutix, Inc. $49,041.90 11/12/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230647
Principal investigator 1 Ocular Therapeutix, Inc. $11,734.20 11/12/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230650
Principal investigator 1 Boehringer Ingelheim International GmbH $5,122.60 11/10/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778414
Principal investigator 1 Boehringer Ingelheim International GmbH $5,122.60 11/10/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778466
Principal investigator 1 Boehringer Ingelheim International GmbH $180.00 11/05/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778412
Principal investigator 1 Boehringer Ingelheim International GmbH $186.00 11/05/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778434
Principal investigator 1 Boehringer Ingelheim International GmbH $210.00 11/05/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778470
Principal investigator 1 Boehringer Ingelheim International GmbH $5,122.60 11/03/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778446
Principal investigator 1 Boehringer Ingelheim International GmbH $5,065.20 11/03/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778460
Principal investigator 1 Boehringer Ingelheim International GmbH $1,817.20 10/29/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778308
Principal investigator 1 Boehringer Ingelheim International GmbH $5,065.20 10/29/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778348
Principal investigator 1 Boehringer Ingelheim International GmbH $1,817.20 10/29/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778388
Principal investigator 1 Boehringer Ingelheim International GmbH $5,065.20 10/29/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778394
Principal investigator 1 Boehringer Ingelheim International GmbH $23.32 10/27/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778532
Principal investigator 1 Boehringer Ingelheim International GmbH $199.80 10/27/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778534
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 10/27/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778536
Principal investigator 1 Boehringer Ingelheim International GmbH $63.80 10/27/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778538
Principal investigator 1 Boehringer Ingelheim International GmbH $2.44 10/27/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778540
Principal investigator 1 Ocular Therapeutix, Inc. $200.00 10/20/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230707
Principal investigator 1 Ocular Therapeutix, Inc. $12,536.00 10/17/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230639
Principal investigator 1 Boehringer Ingelheim International GmbH $308.00 10/15/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778300
Principal investigator 1 Boehringer Ingelheim International GmbH $204.40 10/15/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778302
Principal investigator 1 Boehringer Ingelheim International GmbH $308.00 10/15/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778312
Principal investigator 1 Boehringer Ingelheim International GmbH $64.40 10/15/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778316
Principal investigator 1 Boehringer Ingelheim International GmbH $204.40 10/15/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778318
Principal investigator 1 Boehringer Ingelheim International GmbH $252.00 10/15/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778322
Principal investigator 1 Boehringer Ingelheim International GmbH $236.60 10/15/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778324
Principal investigator 1 Boehringer Ingelheim International GmbH $191.80 10/15/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778328
Principal investigator 1 Boehringer Ingelheim International GmbH $236.60 10/15/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778332
Principal investigator 1 Boehringer Ingelheim International GmbH $236.60 10/15/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778334
Principal investigator 1 Boehringer Ingelheim International GmbH $191.80 10/15/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778336
Principal investigator 1 Boehringer Ingelheim International GmbH $106.40 10/15/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778340
Principal investigator 1 Boehringer Ingelheim International GmbH $191.80 10/15/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778342
Principal investigator 1 Boehringer Ingelheim International GmbH $191.80 10/15/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778344
Principal investigator 1 Boehringer Ingelheim International GmbH $204.40 10/15/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778350
Principal investigator 1 Boehringer Ingelheim International GmbH $106.40 10/15/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778352
Principal investigator 1 Boehringer Ingelheim International GmbH $252.00 10/15/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778354
Principal investigator 1 Boehringer Ingelheim International GmbH $106.40 10/15/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778356
Principal investigator 1 Boehringer Ingelheim International GmbH $308.00 10/15/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778362
Principal investigator 1 Boehringer Ingelheim International GmbH $204.40 10/15/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778366
Principal investigator 1 Boehringer Ingelheim International GmbH $106.40 10/15/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778368
Principal investigator 1 Boehringer Ingelheim International GmbH $236.60 10/15/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778370
Principal investigator 1 Boehringer Ingelheim International GmbH $252.00 10/15/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778374
Principal investigator 1 Boehringer Ingelheim International GmbH $236.60 10/15/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778382
Principal investigator 1 Boehringer Ingelheim International GmbH $308.00 10/15/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778384
Principal investigator 1 Boehringer Ingelheim International GmbH $252.00 10/15/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778398
Principal investigator 1 Ocular Therapeutix, Inc. $2,565.00 10/15/2025 Non-covered Recipient Entity
Bay Area Retina Associates (Walnut Creak) - 20-070
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230711
Principal investigator 1 Ocular Therapeutix, Inc. $2,706.40 10/10/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230635
Principal investigator 1 Ocular Therapeutix, Inc. $12,536.00 10/08/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230626
Principal investigator 1 Ocular Therapeutix, Inc. $550.00 10/08/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230631
Principal investigator 1 Boehringer Ingelheim International GmbH $106.40 10/03/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778304
Principal investigator 1 Boehringer Ingelheim International GmbH $236.60 10/03/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778306
Principal investigator 1 Boehringer Ingelheim International GmbH $106.40 10/03/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778310
Principal investigator 1 Boehringer Ingelheim International GmbH $236.60 10/03/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778314
Principal investigator 1 Boehringer Ingelheim International GmbH $236.60 10/03/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778320
Principal investigator 1 Boehringer Ingelheim International GmbH $106.40 10/03/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778326
Principal investigator 1 Boehringer Ingelheim International GmbH $204.40 10/03/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778330
Principal investigator 1 Boehringer Ingelheim International GmbH $191.80 10/03/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778338
Principal investigator 1 Boehringer Ingelheim International GmbH $191.80 10/03/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778346
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 10/03/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778358
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 10/03/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778360
Principal investigator 1 Boehringer Ingelheim International GmbH $308.00 10/03/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778364
Principal investigator 1 Boehringer Ingelheim International GmbH $204.40 10/03/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778372
Principal investigator 1 Boehringer Ingelheim International GmbH $308.00 10/03/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778376
Principal investigator 1 Boehringer Ingelheim International GmbH $252.00 10/03/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778378
Principal investigator 1 Boehringer Ingelheim International GmbH $252.00 10/03/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778380
Principal investigator 1 Boehringer Ingelheim International GmbH $204.40 10/03/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778386
Principal investigator 1 Boehringer Ingelheim International GmbH $191.80 10/03/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778390
Principal investigator 1 Boehringer Ingelheim International GmbH $252.00 10/03/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778392
Principal investigator 1 Boehringer Ingelheim International GmbH $308.00 10/03/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778396
Principal investigator 1 Ocular Therapeutix, Inc. $550.00 10/01/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230623
Principal investigator 1 Ocular Therapeutix, Inc. $350.00 09/26/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230618
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 09/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778294
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 09/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778296
Principal investigator 1 Boehringer Ingelheim International GmbH $6.96 09/24/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778298
Principal investigator 1 Ocular Therapeutix, Inc. $100.00 09/24/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230606
Principal investigator 1 Ocular Therapeutix, Inc. $3,477.60 09/24/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230610
Principal investigator 1 Ocular Therapeutix, Inc. $550.00 09/24/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230614
Principal investigator 1 Ocular Therapeutix, Inc. $10,840.80 09/12/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230602
Principal investigator 1 Ocular Therapeutix, Inc. $1,540.80 09/03/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230582
Principal investigator 1 Ocular Therapeutix, Inc. $840.00 09/03/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230586
Principal investigator 1 Ocular Therapeutix, Inc. $1,327.00 09/03/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230590
Principal investigator 1 Ocular Therapeutix, Inc. $200.00 09/03/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230593
Principal investigator 1 Ocular Therapeutix, Inc. $14,110.00 09/03/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230598
Principal investigator 1 Boehringer Ingelheim International GmbH $120.13 08/28/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778548
Principal investigator 1 Ocular Therapeutix, Inc. $4,102.20 08/27/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230578
Principal investigator 1 Ocular Therapeutix, Inc. $300.00 08/20/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230574
Principal investigator 1 Ocular Therapeutix, Inc. $58,626.00 08/13/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230568
Principal investigator 1 Ocular Therapeutix, Inc. $4,466.70 08/13/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230571
Principal investigator 1 Ocular Therapeutix, Inc. $200.00 08/06/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230561
Principal investigator 1 Ocular Therapeutix, Inc. $17,347.20 08/06/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230565
Principal investigator 1 Ocular Therapeutix, Inc. $550.00 08/01/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230549
Principal investigator 1 Ocular Therapeutix, Inc. $2,384.80 08/01/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230553
Principal investigator 1 Ocular Therapeutix, Inc. $1,000.00 08/01/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230557
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 07/28/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778246
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 07/28/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778248
Principal investigator 1 Boehringer Ingelheim International GmbH $8,000.00 07/28/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778250
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 07/28/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778252
Principal investigator 1 Boehringer Ingelheim International GmbH $2,000.00 07/28/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778254
Principal investigator 1 Ocular Therapeutix, Inc. $4,102.20 07/25/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230545
Principal investigator 1 Ocular Therapeutix, Inc. $300.00 07/18/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230536
Principal investigator 1 Ocular Therapeutix, Inc. $654.00 07/18/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230540
Principal investigator 1 Boehringer Ingelheim International GmbH $19.67 07/16/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778256
Principal investigator 1 Boehringer Ingelheim International GmbH $5.67 07/16/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778258
Principal investigator 1 Boehringer Ingelheim International GmbH $156.33 07/16/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778260
Principal investigator 1 Boehringer Ingelheim International GmbH $40.13 07/16/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778262
Principal investigator 1 Boehringer Ingelheim International GmbH $15.69 07/16/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778264
Principal investigator 1 Boehringer Ingelheim International GmbH $15.40 07/16/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778266
Principal investigator 1 Boehringer Ingelheim International GmbH $16.77 07/16/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778268
Principal investigator 1 Boehringer Ingelheim International GmbH $20.51 07/16/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778270
Principal investigator 1 Boehringer Ingelheim International GmbH $285.27 07/16/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778272
Principal investigator 1 Boehringer Ingelheim International GmbH $47.25 07/16/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778274
Principal investigator 1 Boehringer Ingelheim International GmbH $8.33 07/16/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778276
Principal investigator 1 Boehringer Ingelheim International GmbH $5.67 07/16/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778278
Principal investigator 1 Boehringer Ingelheim International GmbH $4.33 07/16/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778280
Principal investigator 1 Boehringer Ingelheim International GmbH $4.33 07/16/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778282
Principal investigator 1 Boehringer Ingelheim International GmbH $31.50 07/16/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778284
Principal investigator 1 Boehringer Ingelheim International GmbH $19.67 07/16/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778286
Principal investigator 1 Boehringer Ingelheim International GmbH $8.33 07/16/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778288
Principal investigator 1 Ocular Therapeutix, Inc. $550.00 07/09/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230528
Principal investigator 1 Ocular Therapeutix, Inc. $1,986.80 07/09/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230532
Principal investigator 1 Ocular Therapeutix, Inc. $550.00 07/04/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230523
Principal investigator 1 Ocular Therapeutix, Inc. $4,102.20 07/02/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230516
Principal investigator 1 Ocular Therapeutix, Inc. $1,000.00 07/02/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230520
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778290
Recipient Ocular Therapeutix, Inc. $10,273.86 06/30/2025 Covered Recipient Physician Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250229183
Principal investigator 1 Ocular Therapeutix, Inc. $873.60 06/23/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230474
Principal investigator 1 Ocular Therapeutix, Inc. $540.00 06/23/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230478
Principal investigator 1 Ocular Therapeutix, Inc. $25,684.20 06/13/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230471
Principal investigator 1 Ocular Therapeutix, Inc. $1,000.00 06/11/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230455
Principal investigator 1 Ocular Therapeutix, Inc. $17,332.20 06/11/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230459
Principal investigator 1 Ocular Therapeutix, Inc. $2,078.80 06/11/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230463
Principal investigator 1 Ocular Therapeutix, Inc. $10,134.40 06/11/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230467
Principal investigator 1 Ocular Therapeutix, Inc. $300.00 06/04/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230451
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778292
Principal investigator 1 Ocular Therapeutix, Inc. $18,000.90 05/30/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230447
Principal investigator 1 Boehringer Ingelheim International GmbH $93.28 05/27/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778236
Principal investigator 1 Boehringer Ingelheim International GmbH $159.84 05/27/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778238
Principal investigator 1 Boehringer Ingelheim International GmbH $547.50 05/27/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778240
Principal investigator 1 Boehringer Ingelheim International GmbH $146.16 05/27/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778242
Principal investigator 1 Boehringer Ingelheim International GmbH $3.66 05/27/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778244
Principal investigator 1 Ocular Therapeutix, Inc. $200.00 05/23/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230443
Principal investigator 1 Ocular Therapeutix, Inc. $9,157.50 05/21/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230438
Principal investigator 1 Ocular Therapeutix, Inc. $8,585.10 05/14/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230423
Principal investigator 1 Ocular Therapeutix, Inc. $8,672.40 05/14/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230427
Principal investigator 1 Ocular Therapeutix, Inc. $1,706.00 05/14/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230430
Principal investigator 1 Ocular Therapeutix, Inc. $1,000.00 05/14/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230435
Principal investigator 1 Ocular Therapeutix, Inc. $550.00 05/09/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230419
Principal investigator 1 Boehringer Ingelheim International GmbH $70.00 05/08/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778400
Principal investigator 1 Boehringer Ingelheim International GmbH $70.00 05/08/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778402
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 05/01/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778228
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 05/01/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778230
Principal investigator 1 Boehringer Ingelheim International GmbH $43.00 05/01/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778232
Principal investigator 1 Boehringer Ingelheim International GmbH $23.75 05/01/2025 Non-covered Recipient Entity
Bay Area Retina Associates Walnut Creek
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220778234
Principal investigator 1 Ocular Therapeutix, Inc. $1,439.20 04/30/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230414
Principal investigator 1 Ocular Therapeutix, Inc. $10,898.40 04/23/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230410
Principal investigator 1 Ocular Therapeutix, Inc. $300.00 04/18/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230405
Principal investigator 1 Ocular Therapeutix, Inc. $420.00 04/16/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230401
Principal investigator 1 Ocular Therapeutix, Inc. $550.00 04/11/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230392
Principal investigator 1 Ocular Therapeutix, Inc. $300.00 04/11/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230397
Principal investigator 1 Ocular Therapeutix, Inc. $275.00 04/09/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230373
Principal investigator 1 Ocular Therapeutix, Inc. $1,824.40 04/09/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230379
Principal investigator 1 Ocular Therapeutix, Inc. $8,692.20 04/09/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230382
Principal investigator 1 Ocular Therapeutix, Inc. $1,000.00 04/09/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230387
Principal investigator 1 Ocular Therapeutix, Inc. $39,445.00 04/04/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230367
Principal investigator 1 Ocular Therapeutix, Inc. $1,988.00 04/02/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230355
Principal investigator 1 Ocular Therapeutix, Inc. $1,000.00 04/02/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230359
Principal investigator 1 Ocular Therapeutix, Inc. $1,066.80 04/02/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230363
Principal investigator 1 Ocular Therapeutix, Inc. $3,082.20 03/28/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230507
Principal investigator 1 Ocular Therapeutix, Inc. $100.00 03/28/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230510
Principal investigator 1 Ocular Therapeutix, Inc. $8,204.40 03/19/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230503
Principal investigator 1 Ocular Therapeutix, Inc. $654.00 03/14/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230494
Principal investigator 1 Ocular Therapeutix, Inc. $550.00 03/14/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230498
Principal investigator 1 Ocular Therapeutix, Inc. $1,293.80 03/07/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230489
Principal investigator 1 Ocular Therapeutix, Inc. $1,000.00 03/05/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230482
Principal investigator 1 Ocular Therapeutix, Inc. $1,000.00 03/05/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230485
Principal investigator 1 Ocular Therapeutix, Inc. $3,834.00 02/26/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230348
Principal investigator 1 Ocular Therapeutix, Inc. $60,344.10 02/19/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230343
Principal investigator 1 Ocular Therapeutix, Inc. $1,661.60 02/07/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230336
Principal investigator 1 Alexion Pharmaceuticals, Inc. $32,177.80 02/05/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
A Phase 2, Double Masked, Placebo Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD) No dispute reported 06/30/2026 1185543825
Principal investigator 1 Ocular Therapeutix, Inc. $9,213.20 02/05/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230312
Principal investigator 1 Ocular Therapeutix, Inc. $1,783.40 01/29/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230352
Principal investigator 1 Ocular Therapeutix, Inc. $1,000.00 01/24/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230339
Principal investigator 1 Ocular Therapeutix, Inc. $550.00 01/22/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230324
Principal investigator 1 Ocular Therapeutix, Inc. $17,477.10 01/22/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230327
Principal investigator 1 Ocular Therapeutix, Inc. $1,000.00 01/22/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230332
Principal investigator 1 Ocular Therapeutix, Inc. $865.60 01/17/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230320
Principal investigator 1 Ocular Therapeutix, Inc. $18,263.00 01/14/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230315
Principal investigator 1 Ocular Therapeutix, Inc. $3,620.00 01/13/2025 Non-covered Recipient Entity
BAY AREA RETINA ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230308